Single-blind, placebo-controlled dose-modification study of vigabatrin in refractory epileptic patients

Roberto Michelucci, Paolo Cavaciocchi, Patrizia Riguzzi, Daniela Passarelli, Lucio Parmeggiani, Mario Santangelo, Monica Zamagni, Alfonso Ludice, Carlo Alberto Tassinari

Research output: Contribution to journalArticle

Abstract

Thirty patients with drug-resistant epileptic seizures received vigabatrin as add-on treatment in a single-blind, placebo-controlled dose-modification study. After a 3-month baseline period (1 month run-in, 2 months placebo), the patients were given vigabatrin (2 g/day, fixed dose) for 2 months, followed by a 2- to 6-month dose-titration period to achieve the individual optimal dose. Mean monthly seizure frequency significantly decreased from 29.5 seizures during the placebo period to 12.2 while taking vigabatrin, 2 g daily fixed-dose, and to 8.7 during titration phase with vigabatrin, 3 g daily, on average. Sixteen (53%) patients experienced a 50% or greater reduction in seizure frequency compared with placebo, and 3 (10%) patients reported a relevant improvement in seizure severity and duration while on vigabatrin, 3 g daily; therefore, 19 (63%) patients were allowed to continue the treatment on a long-term basis. Adverse effects, mostly drowsiness and weight gain, occurred particularly at the highest vigabatrin dose, although also in any case of mild severity. Serum phenytoin and phenobarbital levels significantly decreased during vigabatrin treatment. These results suggest that vigabatrin in a dose of 2-3 g daily is an effective and safe antiepileptic drug.

Original languageEnglish
Pages (from-to)248-252
Number of pages5
JournalJournal of Epilepsy
Volume5
Issue number4
DOIs
Publication statusPublished - 1992

Fingerprint

Vigabatrin
Placebos
Seizures
Sleep Stages
Phenytoin
Phenobarbital
Anticonvulsants
Weight Gain
Epilepsy
Therapeutics

Keywords

  • Complex partial seizures
  • Drug interaction
  • Refractory epilepsy
  • Vigabatrin

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Single-blind, placebo-controlled dose-modification study of vigabatrin in refractory epileptic patients. / Michelucci, Roberto; Cavaciocchi, Paolo; Riguzzi, Patrizia; Passarelli, Daniela; Parmeggiani, Lucio; Santangelo, Mario; Zamagni, Monica; Ludice, Alfonso; Tassinari, Carlo Alberto.

In: Journal of Epilepsy, Vol. 5, No. 4, 1992, p. 248-252.

Research output: Contribution to journalArticle

Michelucci, R, Cavaciocchi, P, Riguzzi, P, Passarelli, D, Parmeggiani, L, Santangelo, M, Zamagni, M, Ludice, A & Tassinari, CA 1992, 'Single-blind, placebo-controlled dose-modification study of vigabatrin in refractory epileptic patients', Journal of Epilepsy, vol. 5, no. 4, pp. 248-252. https://doi.org/10.1016/S0896-6974(05)80125-2
Michelucci, Roberto ; Cavaciocchi, Paolo ; Riguzzi, Patrizia ; Passarelli, Daniela ; Parmeggiani, Lucio ; Santangelo, Mario ; Zamagni, Monica ; Ludice, Alfonso ; Tassinari, Carlo Alberto. / Single-blind, placebo-controlled dose-modification study of vigabatrin in refractory epileptic patients. In: Journal of Epilepsy. 1992 ; Vol. 5, No. 4. pp. 248-252.
@article{c318651a6e134fb78954854dc09dc947,
title = "Single-blind, placebo-controlled dose-modification study of vigabatrin in refractory epileptic patients",
abstract = "Thirty patients with drug-resistant epileptic seizures received vigabatrin as add-on treatment in a single-blind, placebo-controlled dose-modification study. After a 3-month baseline period (1 month run-in, 2 months placebo), the patients were given vigabatrin (2 g/day, fixed dose) for 2 months, followed by a 2- to 6-month dose-titration period to achieve the individual optimal dose. Mean monthly seizure frequency significantly decreased from 29.5 seizures during the placebo period to 12.2 while taking vigabatrin, 2 g daily fixed-dose, and to 8.7 during titration phase with vigabatrin, 3 g daily, on average. Sixteen (53{\%}) patients experienced a 50{\%} or greater reduction in seizure frequency compared with placebo, and 3 (10{\%}) patients reported a relevant improvement in seizure severity and duration while on vigabatrin, 3 g daily; therefore, 19 (63{\%}) patients were allowed to continue the treatment on a long-term basis. Adverse effects, mostly drowsiness and weight gain, occurred particularly at the highest vigabatrin dose, although also in any case of mild severity. Serum phenytoin and phenobarbital levels significantly decreased during vigabatrin treatment. These results suggest that vigabatrin in a dose of 2-3 g daily is an effective and safe antiepileptic drug.",
keywords = "Complex partial seizures, Drug interaction, Refractory epilepsy, Vigabatrin",
author = "Roberto Michelucci and Paolo Cavaciocchi and Patrizia Riguzzi and Daniela Passarelli and Lucio Parmeggiani and Mario Santangelo and Monica Zamagni and Alfonso Ludice and Tassinari, {Carlo Alberto}",
year = "1992",
doi = "10.1016/S0896-6974(05)80125-2",
language = "English",
volume = "5",
pages = "248--252",
journal = "Journal of Epilepsy",
issn = "0896-6974",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Single-blind, placebo-controlled dose-modification study of vigabatrin in refractory epileptic patients

AU - Michelucci, Roberto

AU - Cavaciocchi, Paolo

AU - Riguzzi, Patrizia

AU - Passarelli, Daniela

AU - Parmeggiani, Lucio

AU - Santangelo, Mario

AU - Zamagni, Monica

AU - Ludice, Alfonso

AU - Tassinari, Carlo Alberto

PY - 1992

Y1 - 1992

N2 - Thirty patients with drug-resistant epileptic seizures received vigabatrin as add-on treatment in a single-blind, placebo-controlled dose-modification study. After a 3-month baseline period (1 month run-in, 2 months placebo), the patients were given vigabatrin (2 g/day, fixed dose) for 2 months, followed by a 2- to 6-month dose-titration period to achieve the individual optimal dose. Mean monthly seizure frequency significantly decreased from 29.5 seizures during the placebo period to 12.2 while taking vigabatrin, 2 g daily fixed-dose, and to 8.7 during titration phase with vigabatrin, 3 g daily, on average. Sixteen (53%) patients experienced a 50% or greater reduction in seizure frequency compared with placebo, and 3 (10%) patients reported a relevant improvement in seizure severity and duration while on vigabatrin, 3 g daily; therefore, 19 (63%) patients were allowed to continue the treatment on a long-term basis. Adverse effects, mostly drowsiness and weight gain, occurred particularly at the highest vigabatrin dose, although also in any case of mild severity. Serum phenytoin and phenobarbital levels significantly decreased during vigabatrin treatment. These results suggest that vigabatrin in a dose of 2-3 g daily is an effective and safe antiepileptic drug.

AB - Thirty patients with drug-resistant epileptic seizures received vigabatrin as add-on treatment in a single-blind, placebo-controlled dose-modification study. After a 3-month baseline period (1 month run-in, 2 months placebo), the patients were given vigabatrin (2 g/day, fixed dose) for 2 months, followed by a 2- to 6-month dose-titration period to achieve the individual optimal dose. Mean monthly seizure frequency significantly decreased from 29.5 seizures during the placebo period to 12.2 while taking vigabatrin, 2 g daily fixed-dose, and to 8.7 during titration phase with vigabatrin, 3 g daily, on average. Sixteen (53%) patients experienced a 50% or greater reduction in seizure frequency compared with placebo, and 3 (10%) patients reported a relevant improvement in seizure severity and duration while on vigabatrin, 3 g daily; therefore, 19 (63%) patients were allowed to continue the treatment on a long-term basis. Adverse effects, mostly drowsiness and weight gain, occurred particularly at the highest vigabatrin dose, although also in any case of mild severity. Serum phenytoin and phenobarbital levels significantly decreased during vigabatrin treatment. These results suggest that vigabatrin in a dose of 2-3 g daily is an effective and safe antiepileptic drug.

KW - Complex partial seizures

KW - Drug interaction

KW - Refractory epilepsy

KW - Vigabatrin

UR - http://www.scopus.com/inward/record.url?scp=0026448336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026448336&partnerID=8YFLogxK

U2 - 10.1016/S0896-6974(05)80125-2

DO - 10.1016/S0896-6974(05)80125-2

M3 - Article

AN - SCOPUS:0026448336

VL - 5

SP - 248

EP - 252

JO - Journal of Epilepsy

JF - Journal of Epilepsy

SN - 0896-6974

IS - 4

ER -